RE: Freddie flintoff10 Sep 2023 04:26
@Siennaj
You probably need a little bit of perspective here, those in the recent penny placing, even with the retrace following the boiler rooms ongoing departure here, are still as at todays 1.7p Bid sitting on a very nice 70% gain. Not bad.
There is a general perception on many of these boards at LSE that because a companies market cap is low, it somehow makes it a bargain buy. It doesn't! Its low for a reason.
Situation here is that this is a consultancy business and as such they need to keep winning new accounts just to stand still to make up for consultancy contracts coming to an end. Meanwhile the biotech funding drought has added additional pressure to business as its made it materially harder to both retain and win new accounts.
Assuming the cost base remains the same, not sure what deal the new COO recently joined is on, at last financial statement they needed about £600k of new revenue to reach break even. They have just won a £125k contract and a low value deal so still a way to go yet.
The new appointment sounds like a great add to the business and he has financial connections. My call here is that he will find his feet, they will do another penny raise to bolster working capital, he may support alongside plus some options and at that point they will have the funds to diversify more which is something i understand Jim wants to do.
In the meantime the SP remains Volatile not least with the boiler room P&D but the SP will settle back and a SP in the 1.3p range feels more realistic to me until they can diversify.
After all what exactly has changed here in the last few weeks? An additional board member has joined and a £125k order plus an unspecified one - is that worth a 70% increase in its market value? I don't think so, its just as a result of the P&D crew.
Good luck anyhow, the journey has started which is a positive, i might join at the next placing if they can illustrate a solid plan to break even,